Release of interleukin-6 and its soluble receptors by activated peripheral blood monocytes is elevated in hypocholesterolemic hemodialysis patients

American Journal of Nephrology

Volumn 25, Issue 5, 2005, Pages 484-490

  Tsirpanlis, George ^a,d   Chatzipanagiotou, Stylianos ^b   Boufidou, Fotini ^b   Kordinas, Vasileios ^b   Alevyzaki, Fotini ^a   Zoga, Margarita ^b   Kyritsis, Ilias ^a   Ioannou, Dimitris ^c   Fatourou, Alexandra ^a   Nicolaou, Chrysoula ^b  

^a KAT HOSPITAL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c Dragini Clinic   (Greece)

^d NONE   (Greece)

Author keywords

Cardiovascular disease; Cell culture; Cholesterol; Cytokines; Inflammation; Lipids; Peripheral blood mononuclear cell; Renal failure; Reverse epidemiology; Soluble IL 6 receptor; Soluble receptors; Triglycerides

Indexed keywords

CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL CULTURE; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; INFLAMMATION; KIDNEY FAILURE; LIPID BLOOD LEVEL; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUPERNATANT;

ADULT; AGED; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; GLYCOPROTEINS; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, INTERLEUKIN-6; RENAL DIALYSIS; SOLUBILITY;

EID: 26444601352     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087921     Document Type: Article

References (20)

1. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
2. Liu Y, Coresh J, Eustace JA, et al: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004;291:451-459.
3. Hansson KG: Inflammation, atherosclerosis, and coronary disease. N Engl J Med 2005;352:1685-1695.
4. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P: Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant 2003;18:1042-1045.
5. Jones SA, Horiuchi S, Topley N, et al: The soluble interleukin-6 receptor: Mechanisms of production and implications in disease. FASEB J 2001;15:43-58.
6. Jostock T, Mullberg J, Ozbek S, et al: Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268:160-167.
7. Memoli B, Postiglione L, Cianciaruso B, et al: Role of different dialysis membranes in the release of interleukin-6 soluble receptor in uremic patients. Kidney Int 2000;58:417-424.
8. Lessner SM, Prado HL, Waller EK, Galis ZS: Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol 2002;160:2145-2155.
9. Matthews V, Schuster B, Schutze S, et al: Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003;278:38829-38839.
10. von Tresckow B, Kallen KJ, von Strandmann EP, et al: Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol 2004;172:4324-4331.
11. Cherukuri A, Dykstra M, Pierce SK: Floating the raft hypothesis: Lipid rafts play a role in immune cell activation. Immunity 2001;14:657-600.
12. Kim J, Adam RM, Solomon KR, Freeman MR: Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 2004;145:613-619.
13. Reznikov LL, Waksman J, Azam T, et al: Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004;61:324-336.
14. Ambrosch A, Muller R, Freytag C, et al: Small-sized low-density lipoproteins of subclass B from patients with end-stage renal disease effectively augment tumor necrosis factor-alpha-induced adhesive properties in human endothelial cells. Am J Kidney Dis 2002;39:972-984.
15. Liuba P, Persson J, Luoma J, Yla-Herttuala S, Pesonen E: Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima media. Eur Heart J 2004;24:515-521.
16. Liberopoulos E, Siamopoulos K, Elisaf M: Apolipoprotein E and renal disease. Am J Kidney Dis 2004;43:223-233.
17. Axelsson J, Rashid Qureshi A, Suliman ME, et al: Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004;80:1222-1229.
18. Stenvinkel P, Heimburger O, Lindholm B: Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant 2004;19:2181-2183.
19. Wanner C, Quaschning T: Dyslipidemia and renal disease: Pathogenesis and clinical consequences. Curr Opin Nephrol Hypertens 2001;10:195-201.
20. Quaschning T, Schoming M, Keller M, et al: Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. J Am Soc Nephrol 1999;10:322-341.